世界の加齢性黄斑変性症の市場規模は、2023年に108億2000万ドルと評価され、2024年から2030年にかけて8.2%のCAGRで成長すると予測されます。新製品の発売、強力な製品パイプライン、AMDの有病率の増加が、市場の主要な推進要因です。Population Reference Bureauによると、65歳以上のアメリカ人の人口は、2022年の5,800万人から2050年には8,200万人に増加し、47%増加すると推定されています。現在、米国の人口はかつてないほど高齢化しています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Age-Related Macular Degeneration Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Age-Related Macular Degeneration Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Age-Related Macular Degeneration Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Age-Related Macular Degeneration Market: Product Movement Analysis, USD Million, 2023 & 2030
4.3. Eylea
4.3.1. Eylea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Lucentis
4.4.1. Lucentis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Beovu
4.5.1. Beovu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Age-Related Macular Degeneration Market: Disease Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Age-Related Macular Degeneration Market: Disease Movement Analysis, USD Million, 2023 & 2030
5.3. Wet AMD
5.3.1. Wet AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Dry AMD
5.4.1. Dry AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Age-Related Macular Degeneration Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Age-Related Macular Degeneration Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Specialty Pharmacy
6.4.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Age-Related Macular Degeneration Market: Regional Estimates & Trend Analysis
7.1. Age-Related Macular Degeneration Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. UAE
7.6.3.1. UAE Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. South Africa
7.6.4.1. South Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Novartis AG
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Bayer AG
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Pfizer Inc.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Bausch Health Companies Inc.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Regeneron Pharmaceuticals Inc.
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Amgen Inc.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Biogen
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Samsung Bioepis
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
